Henan Hualong Biotechnology Company   Report issue

Government Phase 1
Founded: Henan China (2012)

Organization Overview

First Clinical Trial
2019
NCT03881761
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Henan Hualong Biotechnology Company

Active Ingredients

Drugs in Phase 1 Trials (2)

cd19/cd20 bispecific car-t cells (1 trial)

hiv-1 specific car-t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2